Trials / Completed
CompletedNCT00350831
Study of XL820 Given Orally Daily to Subjects With Solid Tumors
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the KIT Inhibitor XL820 Administered Orally Daily to Subjects With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of the KIT inhibitor XL820 when given orally daily to adults with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL820 |
Timeline
- Start date
- 2006-07-01
- First posted
- 2006-07-11
- Last updated
- 2008-08-18
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00350831. Inclusion in this directory is not an endorsement.